BrainLAB opens new gateway to high-dose radiotherapy
This article was originally published in Clinica
Executive Summary
Targeting high-dose radiotherapy at liver and lung tumours is now a possibility using BrainLAB's ExacTrac X-Ray Adaptive Gating system. Such levels of radiation are traditionally difficult to administer to these tumours, due to respiration-induced movement and the risk of damaging sensitive surrounding tissue. But the Munich, Germany-based company has overcome this problem, and has announced the completion of the first patient treatment programme using the system - carried out with its clinical partners AZ-VUB of Brussels, Belgium.